1
|
Saldaris J, Weisenberg J, Pestana-Knight E, Marsh ED, Suter B, Rajaraman R, Heidary G, Olson HE, Devinsky O, Price D, Jacoby P, Leonard H, Benke TA, Demarest S, Downs J. Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder. J Child Neurol 2021; 36:998-1006. [PMID: 34378447 PMCID: PMC8458223 DOI: 10.1177/08830738211019576] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
CDKL5 deficiency disorder (CDD) results in early-onset seizures and severe developmental impairments. A CDD clinical severity assessment (CCSA) was previously developed with clinician and parent-report items to capture information on a range of domains. Consistent with US Food and Drug Administration (FDA) guidelines, content validation is the first step in evaluating the psychometric properties of an outcome measure. The aim of this study was to validate the content of the clinician-reported items in the CCSA (CCSA-Clinician). Eight neurologists leading the USA CDD Center of Excellence clinics were interviewed using the "think aloud" technique to critique 26 clinician-reported items. Common themes were aggregated, and a literature search of related assessments informed item modifications. The clinicians then participated in 2 consensus meetings to review themes and finalize the items. A consensus was achieved for the content of the CCSA-Clinician. Eight of the original items were omitted, 11 items were added, and the remaining 18 items were revised. The final 29 items were classified into 2 domains: functioning and neurologic impairments. This study enabled refinement of the CCSA-Clinician and provided evidence for its content validity. This preliminary validation is essential before field testing and further validation, in order to advance the instrument toward clinical trial readiness.
Collapse
Affiliation(s)
| | - Judith Weisenberg
- St. Louis Children’s Hospital and Washington University School of Medicine, St Louis, Missouri, USA
| | | | - Eric D. Marsh
- Division of Neurology, Children’s Hospital of Philadelphia and School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Bernhard Suter
- Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas, USA
| | | | - Gena Heidary
- Department of Ophthalmology, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Heather E. Olson
- Department of Neurology, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Orrin Devinsky
- NYU Langone Health and Department of Neurology, New York University, New York, New York, USA
| | - Dana Price
- NYU Langone Health and Department of Neurology, New York University, New York, New York, USA
| | - Peter Jacoby
- Telethon Kids Institute, Perth, Western Australia, Australia
| | - Helen Leonard
- Telethon Kids Institute, Perth, Western Australia, Australia,The University of Western Australia, Perth, Western Australia, Australia
| | - Tim A. Benke
- Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Scott Demarest
- Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Jenny Downs
- Telethon Kids Institute, Perth, Western Australia, Australia,The School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia
| |
Collapse
|
2
|
Crudgington H, Rogers M, Morris H, Gringras P, Pal DK, Morris C. Epilepsy-specific patient-reported outcome measures of children's health-related quality of life: A systematic review of measurement properties. Epilepsia 2020; 61:230-248. [PMID: 31953859 PMCID: PMC7065094 DOI: 10.1111/epi.16430] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 12/23/2019] [Accepted: 12/26/2019] [Indexed: 01/20/2023]
Abstract
OBJECTIVE To identify and appraise published evidence of the measurement properties for epilepsy-specific patient-reported outcome measures (PROMs) of children's health-related quality of life (HRQoL). METHODS We searched multiple databases for studies evaluating the measurement properties of English-language epilepsy-specific PROMs of children's HRQoL. We assessed the methodological quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidance. We extracted data about the content validity, construct validity, internal consistency, test-retest reliability, proxy reliability, responsiveness, and precision, and assessed the measurement properties with reference to standardized criteria. RESULTS We identified 27 papers that evaluated 11 PROMs. Methodological quality was variable. Construct validity, test-retest reliability, and internal consistency were more commonly assessed. Quality of Life in Childhood Epilepsy (QoLCE) questionnaires are parent-reported and evaluated more than other PROMs; QoLCE-55 has good and replicated evidence for structural and construct validity and internal consistency. Health-Related Quality of Life Measure for Children with Epilepsy (CHEQoL) has both child and parent-reported versions and good evidence of content, structural, and construct validity. SIGNIFICANCE This review identified two leading candidate epilepsy-specific PROMs for measuring health-related quality of life in children. Establishing evidence of the responsiveness of PROMs is a priority to help the interpretation of meaningful change scores.
Collapse
Affiliation(s)
- Holly Crudgington
- Basic and Clinical Neuroscience DepartmentInstitute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
| | - Morwenna Rogers
- University of Exeter Medical SchoolUniversity of ExeterExeterUK
| | - Hannah Morris
- University of Exeter Medical SchoolUniversity of ExeterExeterUK
| | - Paul Gringras
- Evelina London Children's HospitalLondonUK
- KCL Institute for Women and Children's HealthLondonUK
| | - Deb K. Pal
- Basic and Clinical Neuroscience DepartmentInstitute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
- Evelina London Children's HospitalLondonUK
- MRC Centre for Neurodevelopmental DisordersKing's College LondonLondonUK
- King's College HospitalLondonUK
| | | |
Collapse
|
3
|
Demarest S, Pestana-Knight EM, Olson HE, Downs J, Marsh ED, Kaufmann WE, Partridge CA, Leonard H, Gwadry-Sridhar F, Frame KE, Cross JH, Chin RFM, Parikh S, Panzer A, Weisenberg J, Utley K, Jaksha A, Amin S, Khwaja O, Devinsky O, Neul JL, Percy AK, Benke TA. Severity Assessment in CDKL5 Deficiency Disorder. Pediatr Neurol 2019; 97:38-42. [PMID: 31147226 PMCID: PMC6659999 DOI: 10.1016/j.pediatrneurol.2019.03.017] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2018] [Revised: 03/18/2019] [Accepted: 03/19/2019] [Indexed: 11/24/2022]
Abstract
BACKGROUND Pathologic mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder, a genetic syndrome associated with severe epilepsy and cognitive, motor, visual, and autonomic disturbances. This disorder is a relatively common genetic cause of early-life epilepsy. A specific severity assessment is lacking, required to monitor the clinical course and needed to define the natural history and for clinical trial readiness. METHODS A severity assessment was developed based on clinical and research experience from the International Foundation for CDKL5 Research Centers of Excellence consortium and the National Institutes of Health Rett and Rett-Related Disorders Natural History Study consortium. An initial draft severity assessment was presented and reviewed at the annual CDKL5 Forum meeting (Boston, 2017). Subsequently it was iterated through four cycles of a modified Delphi process by a group of clinicians, researchers, industry, patient advisory groups, and parents familiar with this disorder until consensus was achieved. The revised version of the severity assessment was presented for review, comment, and piloting to families at the International Foundation for CDKL5 Research-sponsored family meeting (Colorado, 2018). Final revisions were based on this additional input. RESULTS The final severity assessment comprised 51 items that comprehensively describe domains of epilepsy; motor; cognition, behavior, vision, and speech; and autonomic functions. Parental ratings of therapy effectiveness and child and family functioning are also included. CONCLUSIONS A severity assessment was rapidly developed with input from multiple stakeholders. Refinement through ongoing validation is required for future clinical trials. The consensus methods employed for the development of severity assessment may be applicable to similar rare disorders.
Collapse
Affiliation(s)
- Scott Demarest
- Children's Hospital Colorado and University of Colorado School of Medicine Aurora, Colorado; Department of Pediatrics, Aurora, Colorado
| | - Elia M Pestana-Knight
- Cleveland Clinic, Neurological Institute Cleveland, Ohio; Epilepsy Center, Cleveland, Ohio
| | - Heather E Olson
- Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital Boston, Massachusetts
| | - Jenny Downs
- Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia; School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia
| | - Eric D Marsh
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
| | - Walter E Kaufmann
- M.I.N.D. Institute, Department of Neurology, University of California Davis Health System, Sacramento, California; Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia
| | | | - Helen Leonard
- School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia
| | - Femida Gwadry-Sridhar
- Department of Computer Science, University of Western Ontario and Pulse Infoframe, London, Ontario, Canada
| | | | - J Helen Cross
- UCL Great Ormond Street Institute of Child Health & NIHR GOSH BRC, London, UK
| | - Richard F M Chin
- University of Edinburgh and Royal Hospital for Sick Children, Edinburgh, UK
| | | | | | - Judith Weisenberg
- Neurology, Division of Pediatric Neurology, Epilepsy Section, Washington University School of Medicine, St. Louis Children's Hospital, St Louis, Missouri
| | - Karen Utley
- International Foundation for CDKL5 Research, Wadwsorth, Ohio
| | - Amanda Jaksha
- International Foundation for CDKL5 Research, Wadwsorth, Ohio
| | | | - Omar Khwaja
- Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development NORD, Basel, Switzerland
| | - Orrin Devinsky
- Department of Neurology, New York University, New York, New York
| | - Jeffery L Neul
- Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Tennessee
| | - Alan K Percy
- University of Alabama at Birmingham, Pediatrics, Neurology, Neurobiology, Genetics, and Psychology, Birmingham, Alabama
| | - Tim A Benke
- Children's Hospital Colorado and University of Colorado School of Medicine Aurora, Colorado; Department of Pediatrics, Aurora, Colorado; Department of Pharmacology, Aurora, Colorado; Department of Neurology, Aurora, Colorado; Department of Otolaryngology, Aurora, Colorado.
| |
Collapse
|